Cancer cells with defective DNA repair machinery may have found their match in a precision medicine approach that exploits their vulnerabilities. This represents a fundamental shift toward targeting cancer's weaknesses rather than overwhelming healthy tissue with maximum tolerated doses.
The phase Ib TRESR trial tested camonsertib, an ATR kinase inhibitor, combined with reduced-dose gemcitabine in 76 patients whose tumors harbored DNA damage repair gene alterations. ATR kinase normally helps cells survive DNA replication stress, but blocking it in repair-deficient cancer cells creates synthetic lethality. The intermittent dosing schedule—one week on, one week off—allowed neutrophil recovery while maintaining therapeutic pressure. Gynecologic cancers showed particular responsiveness, with some patients achieving tumor control exceeding one year.
This strategy exemplifies synthetic lethality, where two individually non-lethal hits become fatal when combined. Cancer cells with compromised DNA repair lose backup survival mechanisms when ATR is blocked during gemcitabine-induced replication stress. The preclinical work demonstrated that one-third maximum tolerated doses could achieve tumor regression with minimal toxicity, challenging the traditional "more is better" oncology paradigm.
The approach's limitation lies in requiring specific genetic alterations for patient selection, narrowing the eligible population. However, the durability of responses in gynecologic malignancies suggests this combination could transform treatment for patients whose tumors carry DDR mutations. This represents incremental but meaningful progress in personalized cancer therapy, offering hope for patients with historically treatment-resistant tumors while avoiding the devastating side effects of conventional high-dose regimens.